NO20074628L - Formuleringer av octreotid med kontrollert frigjoring - Google Patents

Formuleringer av octreotid med kontrollert frigjoring

Info

Publication number
NO20074628L
NO20074628L NO20074628A NO20074628A NO20074628L NO 20074628 L NO20074628 L NO 20074628L NO 20074628 A NO20074628 A NO 20074628A NO 20074628 A NO20074628 A NO 20074628A NO 20074628 L NO20074628 L NO 20074628L
Authority
NO
Norway
Prior art keywords
controlled release
octreotide
treatment
octreotide formulations
reduction
Prior art date
Application number
NO20074628A
Other languages
English (en)
Inventor
Petr Kuzma
Stephanie Decker
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Publication of NO20074628L publication Critical patent/NO20074628L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Abstract

Det beskrives en formulering av oktreotid eller farmasøytisk akseptable salter derav, som gir kontrollert frigjøring av en terapeutisk effektiv mengde oktreotid over en periode på minst ca. to måneder. Fremgangsmåter for behandling av akromegali, reduksjon av veksthormon, reduksjon av IGF-I og behandling av tilstander assosiert med karsinoide tumorer og vipomer, ved administrering av en formulering av oktreotid med kontrollert frigjøring, beskrives også.
NO20074628A 2005-03-11 2007-09-12 Formuleringer av octreotid med kontrollert frigjoring NO20074628L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66093005P 2005-03-11 2005-03-11
PCT/US2006/008891 WO2006099288A2 (en) 2005-03-11 2006-03-10 Controlled release formulations of octreotide

Publications (1)

Publication Number Publication Date
NO20074628L true NO20074628L (no) 2007-11-27

Family

ID=36992335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074628A NO20074628L (no) 2005-03-11 2007-09-12 Formuleringer av octreotid med kontrollert frigjoring

Country Status (13)

Country Link
US (7) US7452868B2 (no)
EP (3) EP1888043A4 (no)
JP (2) JP4584331B2 (no)
KR (1) KR101399911B1 (no)
CN (2) CN101193626A (no)
AU (4) AU2006223161B2 (no)
CA (1) CA2601304C (no)
EA (1) EA015793B1 (no)
IL (2) IL185800A0 (no)
NO (1) NO20074628L (no)
NZ (1) NZ561400A (no)
UA (1) UA89398C2 (no)
WO (1) WO2006099288A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
US20090092650A1 (en) * 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
KR101399911B1 (ko) 2005-03-11 2014-06-19 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 옥트레오타이드의 방출 조절형 제형
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US9120249B2 (en) * 2007-04-27 2015-09-01 Endo Pharmaceuticals Solutions Inc. Implant device release agents and methods of using same
US20100196264A1 (en) * 2007-05-18 2010-08-05 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
KR20110025974A (ko) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
CA2739181C (en) 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
CA2739179A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of histrelin and methods of use thereof
CN102202645A (zh) * 2008-09-30 2011-09-28 Endo药物方法有限公司 用于输送奥曲肽的可植入装置及其使用方法
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
WO2012074559A2 (en) 2010-12-02 2012-06-07 New York University Treatment of non-proliferative cystic disease
CA2853249A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable tizanidine compositions and methods of treatment thereof
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
AU2014280847B2 (en) * 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
KR20160075665A (ko) 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
EP4331670A2 (en) 2015-01-07 2024-03-06 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023164614A1 (en) * 2022-02-25 2023-08-31 Amryt Endo, Inc. Oral octreotide for treatment of disease

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71736A (en) * 1867-12-03 Improvement in fences
US2168331A (en) 1936-10-17 1939-08-08 Du Pont Cast resin with integral sheen
US2513014A (en) * 1946-11-18 1950-06-27 Abbott Lab Apparatus for implanting medicinal pellets subcutaneously
GB1306541A (en) 1969-01-20 1973-02-14 Ceskoslovenska Akademie Ved Method of manufacturing tubes by centrifugal casting
US3772435A (en) * 1971-11-02 1973-11-13 American Cyanamid Co Method of using steroid acetonides as growth promoting agents
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4131604A (en) 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4386039A (en) 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4743673A (en) 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US4871094A (en) * 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4994028A (en) * 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
US4846793A (en) * 1987-03-18 1989-07-11 Endocon, Inc. Injector for implanting multiple pellet medicaments
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
HU207940B (en) 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5468811A (en) * 1989-11-02 1995-11-21 National Patent Development Corporation Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
DK0550641T3 (da) * 1990-09-28 1994-08-22 Pfizer Dispenseringsanordning indeholdende et hydrofobt medium
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU652984B2 (en) * 1992-01-14 1994-09-15 Endo Pharmaceuticals Solutions Inc. Preparation of homogeneous hydrogel copolymers
JP2530079B2 (ja) * 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション 水分膨潤性親水性製品及び薬物放出装置の製造
CA2134087C (en) * 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5614223A (en) * 1992-05-04 1997-03-25 Digestive Care Inc. Intraoral medicament-releasing device
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE69425781T2 (de) * 1993-06-11 2001-01-04 Nippon Chemicon Understützungs- und Verbindungsgerät für einen Magnetfeldmodulationskopf, der in einer photomagnetischen Aufzeichnung benutzt wird
US5354835A (en) 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JPH0797338A (ja) * 1993-09-20 1995-04-11 Shiseido Co Ltd 徐放性製剤
JPH07252166A (ja) * 1993-09-20 1995-10-03 Shiseido Co Ltd 徐放性製剤
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
EP1007080B1 (en) * 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
EP1629849B2 (en) * 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
US5854127A (en) * 1997-03-13 1998-12-29 Micron Technology, Inc. Method of forming a contact landing pad
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US6822016B2 (en) * 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
US6602694B1 (en) * 1998-07-14 2003-08-05 Amylin Pharmaceuticals, Inc Uncoupling protein 4 (UCP-4)
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
AU770712B2 (en) * 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6361797B1 (en) * 1999-01-28 2002-03-26 Hydro Med Sciences, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
PT1246638E (pt) * 2000-01-10 2004-12-31 Amylin Pharmaceuticals Inc Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia
KR20030009389A (ko) * 2000-03-14 2003-01-29 브루카드 괴케 유문동-유문-십이지장 운동성에 대한 글루카곤 유사펩티드-1 (7-36)의 효과
US6969480B2 (en) 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
AU6323001A (en) * 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE450269T1 (de) * 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
EP1383538A2 (en) 2001-04-01 2004-01-28 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. Oral absorbed drugs
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003243545A1 (en) * 2002-06-14 2003-12-31 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US6942264B1 (en) * 2003-02-10 2005-09-13 Richard Mendez Disposable pet waste receptacle
CA2437639C (en) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
WO2005041873A2 (en) 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1773293B1 (en) * 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
SE0402345L (sv) * 2004-09-24 2006-03-25 Mederio Ag Uppmätt läkemedelsdos
KR101399911B1 (ko) * 2005-03-11 2014-06-19 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 옥트레오타이드의 방출 조절형 제형
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20070037897A1 (en) * 2005-08-12 2007-02-15 Guigui Wang Method for making contact lenses
EP1937297A2 (en) 2005-09-08 2008-07-02 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
US9120249B2 (en) 2007-04-27 2015-09-01 Endo Pharmaceuticals Solutions Inc. Implant device release agents and methods of using same
KR20110025974A (ko) * 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물

Also Published As

Publication number Publication date
US20090087470A1 (en) 2009-04-02
CN101193626A (zh) 2008-06-04
US20200046806A1 (en) 2020-02-13
EP2457564A1 (en) 2012-05-30
AU2011201457B2 (en) 2011-05-19
US20200353055A1 (en) 2020-11-12
US20110009338A1 (en) 2011-01-13
IL214617A0 (en) 2011-09-27
EA015793B1 (ru) 2011-12-30
US7803773B2 (en) 2010-09-28
IL185800A0 (en) 2008-01-06
CN103550137B (zh) 2015-07-29
AU2011201471B2 (en) 2011-05-19
UA89398C2 (uk) 2010-01-25
EP1888043A2 (en) 2008-02-20
US20170100461A1 (en) 2017-04-13
KR101399911B1 (ko) 2014-06-19
KR20080005496A (ko) 2008-01-14
WO2006099288A2 (en) 2006-09-21
AU2011201460B2 (en) 2011-07-28
US8507432B2 (en) 2013-08-13
EP2455072A1 (en) 2012-05-23
AU2011201457A1 (en) 2011-04-21
EA200701956A1 (ru) 2008-02-28
JP2010189401A (ja) 2010-09-02
IL214617A (en) 2016-05-31
AU2011201460A1 (en) 2011-04-21
AU2006223161B2 (en) 2011-05-12
CA2601304A1 (en) 2006-09-21
US20100317579A1 (en) 2010-12-16
US7452868B2 (en) 2008-11-18
WO2006099288A3 (en) 2007-03-01
CA2601304C (en) 2010-08-17
AU2011201471A1 (en) 2011-04-21
CN103550137A (zh) 2014-02-05
JP4584331B2 (ja) 2010-11-17
AU2006223161A1 (en) 2006-09-21
JP2008533046A (ja) 2008-08-21
US20060204540A1 (en) 2006-09-14
NZ561400A (en) 2010-02-26
EP1888043A4 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
NO20074628L (no) Formuleringer av octreotid med kontrollert frigjoring
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20071138L (no) Piperazinderivater som er nyttige for behandling av gastrointestinallidelser
WO2005115361A3 (en) Androgen receptor modulators and method of treating disease using the same
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
NO20060329L (no) Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse
NO20081889L (no) Fast vaksine formulering
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
MX2011010347A (es) Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
SE0101379D0 (sv) Komposition som hämmar utsöndring av magsyra
WO2005009370A3 (en) Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
WO2007002181A3 (en) Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
DK1505973T3 (da) Kombinationer til behandling af multipelt myelom
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application